drugset
drugset / Trial / NCT05659459

The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2

NCT05659459 ↗

Phase 2 Terminated 17 enrolled Kinarus AG
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Clinical trial on safety and efficacy of KIN001 in non-hospitalized patients with COVID-19.

Timeline

Start
2022-08-25
Primary completion
2023-10-01
Completion
2023-10-01

Outcome

Outcome not reported

Stopped (Business): “Sponsor went bankrupt - trial was discontinued due to lack of financing”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pamapimod Small molecule 75 mg Oral
Subject Pioglitazone Small molecule 5 mg Oral

Indications

COVID-19